Key Points
- Director Mikael Dolsten sold 634 Agilent shares at an average price of $151.38, totaling approximately $95,975. His remaining ownership fell 11.41% to 4,924 shares.
- Agilent reported stronger-than-expected quarterly results, with EPS of $1.62 versus the $1.49 consensus and revenue of $1.88 billion. Revenue increased 8.1% year over year, and the company issued fiscal 2026 EPS guidance of $6.18–$6.21.
- Wall Street sentiment remains positive, with an average rating of “Moderate Buy” and an average price target of $170.33, despite the stock trading down 1.4% and opening at $144.79.
Agilent Technologies, Inc. (NYSE:A - Get Free Report) Director Mikael Dolsten sold 634 shares of the stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $151.38, for a total transaction of $95,974.92. Following the sale, the director directly owned 4,924 shares of the company's stock, valued at approximately $745,395.12. This represents a 11.41% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Agilent Technologies Trading Down 1.4%
Agilent Technologies stock opened at $144.79 on Thursday. The firm has a market cap of $40.82 billion, a price-to-earnings ratio of 28.50, a price-to-earnings-growth ratio of 2.24 and a beta of 1.24. Agilent Technologies, Inc. has a 1 year low of $108.35 and a 1 year high of $163.75. The firm's 50 day moving average price is $143.14 and its two-hundred day moving average price is $128.35. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.56 and a current ratio of 2.05.
Agilent Technologies (NYSE:A - Get Free Report) last announced its quarterly earnings data on Wednesday, August 26th. The medical research company reported $1.62 EPS for the quarter, beating analysts' consensus estimates of $1.49 by $0.13. The company had revenue of $1.88 billion during the quarter, compared to the consensus estimate of $1.84 billion. Agilent Technologies had a return on equity of 24.45% and a net margin of 19.53%.The company's quarterly revenue was up 8.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.37 EPS. Agilent Technologies has set its Q4 2026 guidance at 1.710-1.740 EPS and its FY 2026 guidance at 6.180-6.210 EPS. On average, research analysts predict that Agilent Technologies, Inc. will post 6.2 EPS for the current fiscal year.
Institutional Investors Weigh In On Agilent Technologies
Several hedge funds have recently bought and sold shares of A. Brighton Jones LLC boosted its position in Agilent Technologies by 6.1% during the 4th quarter. Brighton Jones LLC now owns 4,663 shares of the medical research company's stock worth $626,000 after acquiring an additional 270 shares during the period. Jones Financial Companies Lllp lifted its position in shares of Agilent Technologies by 15.9% in the first quarter. Jones Financial Companies Lllp now owns 5,610 shares of the medical research company's stock worth $602,000 after purchasing an additional 769 shares in the last quarter. Geneos Wealth Management Inc. lifted its position in shares of Agilent Technologies by 54.8% in the first quarter. Geneos Wealth Management Inc. now owns 599 shares of the medical research company's stock worth $70,000 after purchasing an additional 212 shares in the last quarter. Acadian Asset Management LLC boosted its holdings in shares of Agilent Technologies by 16.5% during the first quarter. Acadian Asset Management LLC now owns 5,352 shares of the medical research company's stock worth $625,000 after purchasing an additional 758 shares during the period. Finally, Sivia Capital Partners LLC purchased a new position in Agilent Technologies during the second quarter valued at approximately $273,000.
Wall Street Analyst Weigh In
A number of equities analysts recently weighed in on the company. Jefferies Financial Group initiated coverage on Agilent Technologies in a research note on Thursday, July 9th. They issued a "hold" rating and a $135.00 price target on the stock. JPMorgan Chase & Co. upped their price objective on shares of Agilent Technologies from $180.00 to $190.00 and gave the company an "overweight" rating in a research note on Thursday, August 27th. Robert W. Baird raised their target price on shares of Agilent Technologies from $155.00 to $156.00 and gave the stock an "outperform" rating in a report on Tuesday, May 26th. Barclays lifted their target price on shares of Agilent Technologies from $150.00 to $175.00 and gave the stock an "overweight" rating in a research report on Thursday, August 27th. Finally, Wolfe Research restated a "hold" rating on shares of Agilent Technologies in a report on Tuesday, June 2nd. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $170.33.
Get Our Latest Analysis on Agilent Technologies
Agilent Technologies Company Profile
(
Get Free Report)
Agilent Technologies, Inc is a global provider of analytical instruments, laboratory software, consumables and services used by organizations in the life sciences, diagnostics, pharmaceutical, chemical, environmental and food industries. Its solutions help customers analyze the composition and quality of substances, develop and manufacture products, and conduct research and testing.
The company's offerings include liquid and gas chromatography systems, mass spectrometry instruments, spectroscopy and atomic analysis equipment, automated electrophoresis systems, laboratory informatics software, columns and other consumables.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
